Capillary blood sampling is one of the most common clinical procedures, with an estimated 9.2 billion safety lancets used globally in 2023. Yet needlestick injuries and device reuse still present risks in high-throughput settings such as diagnostic centres, hospital wards, and home care.

Marldell Limited has developed the Halocet range of sterile single-use lancets in 16G, 21G, 28G, and 30G formats, covering applications from high-volume pathology draws to low-volume neonatal and geriatric sampling.

The inspiration behind the Halocet redesign stems from a profound appreciation of the intersection between human-centred design and the realities of high-volume medical manufacturing. Conducting field research and interviews with healthcare professionals and patients across diverse world regions highlighted a universal truth: a medical device must be as intuitive and comforting to the user as it is clinically effective. Whether mitigating patient visual anxiety in urban hospitals or ensuring ergonomic, foolproof operation for nurses in resource-constrained rural clinics, these firsthand insights helped shape the functional and emotional benchmarks the new design needed to achieve.

Equally transformative was embedding within the production ecosystem to understand how these human requirements translate into physical reality. Witnessing high-volume manufacturing operate at a staggering scale, where multi-cavity tools and high-speed automated assembly systems can output 1,000 devices per minute, reinforced the importance of precision engineering and manufacturing optimization. Collaboration with toolmakers, automation engineers, and quality specialists inspired a design philosophy focused on streamlining components for rapid injection molding and automated vision inspection, proving that life-saving accessibility and uncompromising design quality can coexist at a global scale.

Protected by patents in key markets and currently in pre-production, Halocet is expected to enter regulatory review in 2026. This article outlines its safety design, clinical positioning, and potential benefits for infection control and workflow efficiency.

Clinical Context: Needlestick Risk and Device Limitations

Ongoing safety gaps in current lancet technologies

Despite regulations such as the EU Sharps Directive and OSHA’s Bloodborne Pathogens Standard, sharps injuries from lancets still occur. Common causes include unclear status indicators, accidental pre-activation, and incomplete needle retraction, all of which increase exposure risk to bloodborne pathogens such as HBV, HCV, and HIV.

The current landscape of safety lancets is broadly divided into two categories:

- Pressure-activated devices: These trigger on skin contact. They are often cost-effective but offer less control over timing and can increase anxiety, especially in paediatric and geriatric patients.

- Push-button devices: These add a deliberate activation step and are generally preferred in professional settings, with adoption increasingly shifting toward top-activated designs.

Across both categories, weaknesses often include poor used-versus-unused visibility, limited tamper evidence, and inconsistent needle guidance. These gaps create demand for safer devices that do not add procedural complexity.

Halocet Device Architecture and Safety Features

Safety mechanisms designed to address key failure modes

Halocet uses a top-activated push-button design with integrated safeguards aimed at reducing the main risks seen with existing single-use lancets.

- Halo safety seal: A tear-off ring provides tamper evidence and confirms that the device has not been primed or used.

- Tri-state status indication: Visible changes in the housing show whether the device is unused, primed, or used, reducing reliance on colour alone.

- Guided needle path: A channeled guide helps deliver more consistent penetration depth and may reduce tissue trauma, especially in neonatal and fragile-skin patients.

- Automatic locking and retraction: After activation, the needle retracts and the device locks permanently, preventing re-exposure without relying on user action.

The four gauge options support low-volume fingerstick testing, standard laboratory capillary draws, and higher-volume pathology or blood banking applications.

Comparative Performance and Clinical Implications

Comparison with established devices

In a structured Pugh analysis against five established safety lancets, Halocet achieved the highest net score (+5), with no negative ratings across cost, comfort, ease of use, safety, and versatility.

Its strongest advantages were patient comfort, a layered safety profile, and broad clinical applicability across common capillary sampling uses, from glucose and haemoglobin testing to neonatal screening.

Manufacturing and Supply Chain Considerations

Halocet’s patented single-axis assembly is designed for high-speed automated production and may lower setup costs by more than 50% compared with similar premium devices, potentially enabling competitive pricing without compromising safety.

This manufacturing-first mindset was directly influenced by close collaboration with automation engineers and production specialists during the development process. Understanding the realities of scaling medical devices for global healthcare systems reinforced the importance of simplifying assembly without sacrificing functionality or patient safety.

The initial launch is planned for the United States, followed by expansion into Europe and Asia. Adoption will depend on regulatory clearance, procurement acceptance, and real-world performance after launch.